VistaGen Therapeutics
VTGN
42 hedge funds and large institutions have $90.8M invested in VistaGen Therapeutics in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 11 closing their positions.
265% more call options, than puts
Call options by funds: $3.76M | Put options by funds: $1.03M
1% more capital invested
Capital invested by funds: $90.1M → $90.8M (+$739K)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
1.19% less ownership
Funds ownership: 65.16% → 63.97% (-1.2%)
9% less funds holding
Funds holding: 46 → 42 (-4)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.39M |
| 2 |
Renaissance Technologies
New York
|
+$528K |
| 3 |
SC
Stempoint Capital
New York
|
+$281K |
| 4 |
Millennium Management
New York
|
+$175K |
| 5 |
State Street
Boston,
Massachusetts
|
+$164K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.44M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$748K |
| 3 |
AC
Armistice Capital
New York
|
-$548K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$524K |
| 5 |
Two Sigma Investments
New York
|
-$229K |
VTGN Hedge Fund Activity: Q1 2024 in Review
42 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2024, worth a combined $90.8M — up 0.82% from $90.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VTGN and 7 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 11 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.39M. The largest seller was Nantahala Capital Management, cutting an estimated $1.44M.
- 42 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2024, down from 46 in Q4 2023.
- Funds reported $90.8M of VistaGen Therapeutics stock for Q1 2024, up 0.82% quarter-over-quarter.
- 7 funds opened new VistaGen Therapeutics positions in Q1 2024 and 11 closed out, a net change of -4 holders.
- The largest VistaGen Therapeutics buyer in Q1 2024 was Susquehanna International Group, an estimated $1.39M added.
- The largest VistaGen Therapeutics seller in Q1 2024 was Nantahala Capital Management, an estimated $1.44M sold.
Based on aggregated 13F filings for Q1 2024.